Another randomized, controlled, open‐label, phase 3 trial (NCT01828112) for patients with ALK‐rearranged stage IIIB or IV NSCLC who had received previous chemotherapy and crizotinib but had disease progression also indicated that compared with chemotherapy, ceritinib significantly improved their prognosis.20 The gene discussed is ALK; the disease is non-small cell lung carcinoma.